850991-41-2

Usage

Uses

Used in Organic Synthesis:
5-isopropoxypyridin-3-ylboronic acid is used as a building block for the synthesis of complex organic molecules. Its boronic acid functional group allows for cross-coupling reactions, facilitating the formation of carbon-carbon bonds and the construction of diverse molecular frameworks.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-isopropoxypyridin-3-ylboronic acid is utilized as a precursor for the synthesis of biologically active molecules. Its unique structure and reactivity enable the development of novel drug candidates with potential therapeutic applications.
Used as a Ligand in Catalysis:
5-isopropoxypyridin-3-ylboronic acid is employed as a ligand in catalytic processes, enhancing the efficiency and selectivity of various chemical reactions. Its presence can modulate the activity of catalysts, enabling the synthesis of specific products with improved yields and reduced side reactions.
Used in Drug Development:
5-isopropoxypyridin-3-ylboronic acid is used as a starting material for the development of new drugs. Its ability to form carbon-carbon bonds and its compatibility with various synthetic routes make it a promising candidate for the creation of innovative pharmaceutical agents with improved efficacy and selectivity.
Used in Agrochemicals:
In the agrochemical industry, 5-isopropoxypyridin-3-ylboronic acid is utilized for the synthesis of novel agrochemicals, such as pesticides and herbicides. Its reactivity and structural diversity contribute to the development of more effective and environmentally friendly products for agricultural applications.

Upstream product

• 5419-55-6 Triisopropyl borate 
• 212332-40-6 3-bromo-5-isopropoxypyridine 

Relevant academic research and scientific papers

AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptable salts thereof. The aryl group can be a phenyl ring or a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas (1 or 2), as described herein. The compounds of Formulas (1 and 2) are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.